SPRC Stock Catalyst: SciSparc Subsidiary NeuroThera Labs Completes Acquisition of 54% Interest in CliniQuantum

SciSparc Ltd. (Nasdaq: SPRC) through its subsidiary NeuroThera Labs Inc. (TSXV: NTLX) completed the acquisition of approximately 54% interest in CliniQuantum Ltd. on June 04, 2026. The transaction involved the issuance of 56,375 ordinary shares and 56,600,000 common shares, along with a cash payment of CAD$9,459,954.20 (equivalent to US$2,500,000) at CAD$0.05 per common share.

The total consideration for the acquisition included both the shares issued and the cash payment. NeuroThera Labs issued 56,375 ordinary shares and 56,600,000 common shares as part of the deal. Additionally, a cash amount of CAD$9,459,954.20 was paid, which is equivalent to US$2,500,000 at the exchange rate of CAD$0.05 per common share.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.